Literature DB >> 27349634

Abnormal activation of calpain and protein kinase Cα promotes a constitutive release of matrix metalloproteinase 9 in peripheral blood mononuclear cells from cystic fibrosis patients.

Monica Averna1, Margherita Bavestrello2, Federico Cresta3, Marco Pedrazzi2, Roberta De Tullio4, Laura Minicucci3, Bianca Sparatore4, Franca Salamino4, Sandro Pontremoli2, Edon Melloni4.   

Abstract

Matrix metalloproteinase 9 (MMP9) is physiologically involved in remodeling the extracellular matrix components but its abnormal release has been observed in several human pathologies. We here report that peripheral blood mononuclear cells (PBMCs), isolated from cystic fibrosis (CF) patients homozygous for F508del-cystic fibrosis transmembrane conductance regulator (CFTR), express constitutively and release at high rate MMP9 due to the alteration in their intracellular Ca(2+) homeostasis. This spontaneous and sustained MMP9 secretion may contribute to the accumulation of this protease in fluids of CF patients. Conversely, in PBMCs isolated from healthy donors, expression and secretion of MMP9 are undetectable but can be evoked, after 12 h of culture, by paracrine stimulation which also promotes an increase in [Ca(2+)]i. We also demonstrate that in both CF and control PBMCs the Ca(2+)-dependent MMP9 secretion is mediated by the concomitant activation of calpain and protein kinase Cα (PKCα), and that MMP9 expression involves extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) phosphorylation. Our results are supported by the fact that either the inhibition of Ca(2+) entry or chelation of [Ca(2+)]i as well as the inhibition of single components of the signaling pathway or the restoration of CFTR activity all promote the reduction of MMP9 secretion.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Calcium; Calpain; Cystic fibrosis; MMP9; PBMCs; PKC

Mesh:

Substances:

Year:  2016        PMID: 27349634     DOI: 10.1016/j.abb.2016.06.015

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  4 in total

1.  Whole-blood transcriptomic responses to lumacaftor/ivacaftor therapy in cystic fibrosis.

Authors:  Benjamin T Kopp; James Fitch; Lisa Jaramillo; Chandra L Shrestha; Frank Robledo-Avila; Shuzhong Zhang; Sabrina Palacios; Fred Woodley; Don Hayes; Santiago Partida-Sanchez; Octavio Ramilo; Peter White; Asuncion Mejias
Journal:  J Cyst Fibros       Date:  2019-08-29       Impact factor: 5.482

Review 2.  Rescuing mitochondria in traumatic brain injury and intracerebral hemorrhages - A potential therapeutic approach.

Authors:  Meenakshi Ahluwalia; Manish Kumar; Pankaj Ahluwalia; Scott Rahimi; John R Vender; Raghavan P Raju; David C Hess; Babak Baban; Fernando L Vale; Krishnan M Dhandapani; Kumar Vaibhav
Journal:  Neurochem Int       Date:  2021-09-22       Impact factor: 3.921

3.  An 8-ferroptosis-related genes signature from Bronchoalveolar Lavage Fluid for prognosis in patients with idiopathic pulmonary fibrosis.

Authors:  Yaowu He; Yu Shang; Yupeng Li; Menghan Wang; Dongping Yu; Yi Yang; Shangwei Ning; Hong Chen
Journal:  BMC Pulm Med       Date:  2022-01-05       Impact factor: 3.317

Review 4.  Immunomodulation in Cystic Fibrosis: Why and How?

Authors:  Vincent D Giacalone; Brian S Dobosh; Amit Gaggar; Rabindra Tirouvanziam; Camilla Margaroli
Journal:  Int J Mol Sci       Date:  2020-05-08       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.